| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |